| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453893 | Lung Cancer | 2018 | 7 Pages |
Abstract
The present study demonstrated the upfront SRS strategy to offer a minimally invasive and effective treatment option for EGFR-mutant lung adenocarcinoma patients with limited BM. EGFR-TKI naïve patients were found to be a distinct subgroup for which a longer survival time and durable intracranial disease control can be expected.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Shoji Yomo, Kyota Oda,